# Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia

> **NCT05278156** · PHASE2 · COMPLETED · sponsor: **Celon Pharma SA** · enrollment: 189 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** CPL500036 - low dose
- **DRUG:** CPL500036 - high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05278156
- **Lead sponsor:** Celon Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-19
- **Primary completion:** 2024-06-05
- **Final completion:** 2024-06-19
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05278156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05278156, "Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05278156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*